Lexicon Pharmaceuticals Inc. (LXRX)

Insider Trading, NYSE, Markets, Stock Trader On The Phone

Hedge Fund and Insider Trading News: Bill Ackman, Jana Partners, BlueCrest Capital Management, Iqvia Holdings Inc (IQV), Twelve Seas Investment Company (TWLVU), ABIOMED, Inc. (ABMD), and More

Bill Ackman Makes More Layoffs at His Pershing Square Hedge Fund (CNBC) Billionaire hedge fund manager William Ackman, whose investment assets have shrunk......(read more)

June 27 - Hedge Funds, Insider Trading - Comments

Insider Trading Wall Street Trader Panic

Hedge Fund and Insider Trading News: Paul Tudor Jones, Rob Citrone, Facebook, Inc. (FB), Christopher & Banks Co. (CBK), Lexicon Pharmaceuticals, Inc. (LXRX), and More

‘Capitalism May Need Modernizing,’ Says Billionaire Hedge Fund Manager Paul Tudor Jones (CNBC) The 50-year-old definition of capitalism in......(read more)

June 12 - Hedge Funds, Insider Trading - Comments

biotech, shares, market, amgen, percent, technical, economy, pharmaceutical, rate, quote, producer, drag, business, bio, capitalization, tech, biotechnology, sector, gain,,

Here’s What’s Next For Lexicon Pharmaceuticals, Inc. (LXRX) And Dynavax Technologies Corporation (DVAX)

Two companies have logged strong starts to the week in the biotech space so far, and both are moving on FDA driven catalysts. Here’s a look at these......(read more)

March 1 - News, Stock Analysis - Comments

Biotech Movers And Shakers: Lexicon Pharmaceuticals, Inc. (LXRX) And Neuroderm Ltd (NDRM)

Right then, it’s time to take a look at who moved during the start of this week, and what’s driving the action in the biotech sector. In a continuation......(read more)

December 6 - Market Movers, News, Stock Analysis - Comments

pharmacist, medical, retail, worker, team, young, staff, lab, chemistry, business, drug, chemist, adult, teamwork, drugstore, service,

Two Biotechs With Bad News This Week: What Happens Now?

When things go well in biotech, it can be a great ride. When things repeatedly go well, however, it can be easy to forget how quickly, and how frequently......(read more)

September 16 - News, Stock Analysis - Comments

pharmacist, medical, retail, worker, team, young, staff, lab, chemistry, business, drug, chemist, adult, teamwork, internet, male, drugstore, service,

Delving Into The Lexicon Pharmaceuticals, Inc. (LXRX) Data

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) gained considerably at the end of last week on the back of a data release from its ongoing type 1 diabetes......(read more)

September 13 - News, Stock Analysis - Comments

These Biotech Stocks Move in Opposing Directions Today and Hedge Funds Say You Should Bet on One of Them

Shares of Heron Therapeutics Inc (NASDAQ:HRTX) are up by more than 20% in early trading, following positive Phase 2 reports on HTX-011, an anesthetic......(read more)

September 23 - Hedge Funds, News - Comments

Lexicon Pharmaceuticals, Inc. (LXRX) Flies On Cancer Drug Study Results; Hedge Funds Saw This Coming

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) are flying high today, gaining nearly 60% on Monday, as the company announced positive results for......(read more)

August 3 - Hedge Funds, News - Comments

Nektar Therapeutics (NKTR): Insiders Aren’t Crazy About It But Hedge Funds Love It

Is Nektar Therapeutics (NASDAQ:NKTR) a good investment? Now, according to many of your peers, hedge funds are assumed to be useless, outdated investment......(read more)

September 17 - News - Comments

Acorda Therapeutics Inc (ACOR): Insiders Aren’t Crazy About It But Hedge Funds Love It

To many investors, hedge funds are assumed to be bloated, outdated investment tools of a forgotten age. Although there are In excess of 8,000 hedge funds......(read more)

September 11 - News - Comments

PDL BioPharma Inc. (PDLI): Hedge Fund and Insider Sentiment Unchanged, What Should You Do?

Should PDL BioPharma Inc. (NASDAQ:PDLI) investors track the following data? In the eyes of many market players, hedge funds are seen as overrated, old......(read more)

September 3 - News - Comments

Santarus, Inc. (SNTS): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?

What should a smart Santarus, Inc. (NASDAQ:SNTS) investor do? In the financial world, there are a multitude of gauges investors can use to watch publicly......(read more)

August 30 - News - Comments

Hedge Funds Are Selling Sarepta Therapeutics Inc (SRPT)

Is it smart to be bullish on Sarepta Therapeutics Inc (NASDAQ:SRPT)? If you were to ask many of your fellow readers, hedge funds are seen as overrated......(read more)

August 30 - News - Comments

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc. (LXRX), Pfizer Inc. (PFE), GlaxoSmithKline plc (ADR) (GSK): Why Clinical Trials Fail

Drugs fail their clinical trials for all kinds of reasons. Sometimes, it’s related to efficacy; sometimes, it’s safety related. Most of the......(read more)

August 30 - News - Comments

What Hedge Funds Think About VIVUS, Inc. (VVUS)

Are you curious what the richest investors think about VIVUS, Inc. (NASDAQ:VVUS)? In the 21st century investor’s toolkit, there are dozens of metrics......(read more)

August 22 - News - Comments

Lexicon Pharmaceuticals, Inc. (LXRX), Merck & Co., Inc. (MRK): The Worst-Performing Biotech Stocks of the Last Decade

Suppose we filled a jar with slips of paper with the names of biotech companies that have been around for at least 10 years and with a market cap of at......(read more)

July 24 - News - Comments

Is Nektar Therapeutics (NKTR) Going to Burn These Hedge Funds?

Nektar Therapeutics (NASDAQ:NKTR) was in 8 hedge funds’ portfolio at the end of March. NKTR has experienced a decrease in support from the world......(read more)

June 12 - News - Comments

Amarin Corporation plc (ADR) (AMRN), Lexicon Pharmaceuticals, Inc. (LXRX): Which of These Billion-Dollar Biotechs Is a Buy?

Regardless of Anchor, Things Are Looking Up! It has been a rough year for Amarin Corporation plc (ADR) (NASDAQ:AMRN) and its long-term investors. The......(read more)

June 3 - News - Comments

Posts Tagged ‘Lexicon Pharmaceuticals Inc. (LXRX)’

Hedge Fund and Insider Trading News: Bill Ackman, Jana Partners, BlueCrest Capital Management, Iqvia Holdings Inc (IQV), Twelve Seas Investment Company (TWLVU), ABIOMED, Inc. (ABMD), and More

Hedge Fund and Insider Trading News: Paul Tudor Jones, Rob Citrone, Facebook, Inc. (FB), Christopher & Banks Co. (CBK), Lexicon Pharmaceuticals, Inc. (LXRX), and More

Here’s What’s Next For Lexicon Pharmaceuticals, Inc. (LXRX) And Dynavax Technologies Corporation (DVAX)

Biotech Movers And Shakers: Lexicon Pharmaceuticals, Inc. (LXRX) And Neuroderm Ltd (NDRM)

Two Biotechs With Bad News This Week: What Happens Now?

Delving Into The Lexicon Pharmaceuticals, Inc. (LXRX) Data

These Biotech Stocks Move in Opposing Directions Today and Hedge Funds Say You Should Bet on One of Them

Lexicon Pharmaceuticals, Inc. (LXRX) Flies On Cancer Drug Study Results; Hedge Funds Saw This Coming

Nektar Therapeutics (NKTR): Insiders Aren’t Crazy About It But Hedge Funds Love It

Acorda Therapeutics Inc (ACOR): Insiders Aren’t Crazy About It But Hedge Funds Love It

PDL BioPharma Inc. (PDLI): Hedge Fund and Insider Sentiment Unchanged, What Should You Do?

Santarus, Inc. (SNTS): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?

Hedge Funds Are Selling Sarepta Therapeutics Inc (SRPT)

Lexicon Pharmaceuticals, Inc. (LXRX), Pfizer Inc. (PFE), GlaxoSmithKline plc (ADR) (GSK): Why Clinical Trials Fail

What Hedge Funds Think About VIVUS, Inc. (VVUS)

Lexicon Pharmaceuticals, Inc. (LXRX), Merck & Co., Inc. (MRK): The Worst-Performing Biotech Stocks of the Last Decade

Is Nektar Therapeutics (NKTR) Going to Burn These Hedge Funds?

Amarin Corporation plc (ADR) (AMRN), Lexicon Pharmaceuticals, Inc. (LXRX): Which of These Billion-Dollar Biotechs Is a Buy?

Santarus, Inc. (SNTS): Insiders Are Buying, Should You?

This Metric Says You Are Smart to Buy Sarepta Therapeutics Inc (SRPT)

Pacific Biosciences of California (PACB), Lexicon Pharmaceuticals, Inc. (LXRX): 3 Stocks With Insider Interest